Boston Scientific Corp. — 四半期決算報告書 (NYSE:BSX)

チャート全体を表示

Financials

概要明細書統計

期次年次

Market Capitalization 95.03 B
Employee 59 K
Founded 1979
CEO Michael F. Mahoney
Website www.bostonscientific.com
Headquarter Delaware, United States
FIGI BBG000C0LW92
Industry Technology

総売上高

当期純利益

1株当たり基本利益（基本EPS）

有利子負債合計

フリーキャッシュフロー

現金および現金同等物

95.03 B 時価総額

株価収益率

49.15

売上高対価格比率

7.1

Boston Scientific Corporation

Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator. Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen. BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware.